JAGGED1 expression is associated with prostate cancer metastasis and recurrence

被引:285
作者
Santagata, S
Demichelis, F
Riva, A
Varambally, S
Hofer, MD
Kutok, JL
Kim, R
Tang, J
Montie, JE
Chinnaiyan, AM
Rubin, MA
Aster, JC
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Childrens Hosp, Childrens Hosp Informat Program, Boston, MA USA
[3] IRST Ist Ric Sci & Tecnol, Trent, Italy
[4] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[5] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI USA
关键词
D O I
10.1158/0008-5472.CAN-04-2500
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies suggest that NOTCH signaling can promote epithelial-mesenchymal transitions and augment signaling through AKT, an important growth and survival pathway in epithelial cells and prostate cancer in particular. Here we show that JAGGED1, a NOTCH receptor ligand, is significantly more highly expressed in metastatic prostate cancer as compared with localized prostate cancer or benign prostatic tissues, based on immunohistochemical analysis of JAGGED1 expression in human tumor samples from 154 men. Furthermore, high JAGGED1 expression in a subset of clinically localized tumors was significantly associated with recurrence, independent of other clinical parameters. These findings support a model in which dysregulation of JAGGED1 protein levels plays a role in prostate cancer progression and metastasis and suggest that JAGGED1 may be a useful marker in distinguishing indolent and aggressive prostate cancers.
引用
收藏
页码:6854 / 6857
页数:4
相关论文
共 21 条
  • [1] The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation
    Ascano, JM
    Beverly, LJ
    Capobianco, AJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (10) : 8771 - 8779
  • [2] Bauer KD, 2000, CLIN CANCER RES, V6, P3552
  • [3] Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
    Bhattacharjee, A
    Richards, WG
    Staunton, J
    Li, C
    Monti, S
    Vasa, P
    Ladd, C
    Beheshti, J
    Bueno, R
    Gillette, M
    Loda, M
    Weber, G
    Mark, EJ
    Lander, ES
    Wong, W
    Johnson, BE
    Golub, TR
    Sugarbaker, DJ
    Meyerson, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13790 - 13795
  • [4] Molecular determinants of resistance to antiandrogen therapy
    Chen, CD
    Welsbie, DS
    Tran, C
    Baek, SH
    Chen, R
    Vessella, R
    Rosenfeld, MG
    Sawyers, CL
    [J]. NATURE MEDICINE, 2004, 10 (01) : 33 - 39
  • [5] Delineation of prognostic biomarkers in prostate cancer
    Dhanasekaran, SM
    Barrette, TR
    Ghosh, D
    Shah, R
    Varambally, S
    Kurachi, K
    Pienta, KJ
    Rubin, MA
    Chinnaiyan, AM
    [J]. NATURE, 2001, 412 (6849) : 822 - 826
  • [6] Human ligands of the Notch receptor
    Gray, GE
    Mann, RS
    Mitsiadis, E
    Henrique, D
    Carcangiu, ML
    Banks, A
    Leiman, J
    Ward, D
    Ish-Horowitz, D
    Artavanis-Tsakonas, S
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (03) : 785 - 794
  • [7] Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.3.CO
  • [8] 2-D
  • [9] LaTulippe E, 2002, CANCER RES, V62, P4499
  • [10] The Notch ligands, Jagged and Delta, are sequentially processed by α-secretase and presenilin/γ-secretase and release signaling fragments
    LaVoie, MJ
    Selkoe, DJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (36) : 34427 - 34437